Addition Therapeutics, Inc.

Based in the US, Addition Therapeutics focuses on advanced genetic medicine utilizing its proprietary all-RNA PRINT™ platform to develop innovative therapeutics aimed at chronic and rare diseases. Founded in 2021 in South San Francisco, US, Addition Therapeutics specializes in genetic medicine, leveraging its proprietary technology for therapeutic development. The company received USD 100 mn in funding in December 2025 from investors including SR One and Abingworth. Addition Therapeutics specializes in advanced genetic medicine through its proprietary all-RNA PRINT™ platform, utilizing non-viral, lipid nanoparticle (LNP) technology to develop innovative therapeutics.

The core offerings focus on creating safer, durable, one-time therapies for chronic and rare diseases, facilitating precise RNA-mediated transgene insertion for targeted genetic interventions. This technology serves a diverse client base, including pharmaceutical companies and research institutions, particularly in North America and Europe, addressing significant demand for novel therapeutic solutions. Addition Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations. Their business model is characterized by B2B partnerships, including joint development agreements and licensing arrangements, allowing clients to leverage the PRINT platform.

The company’s innovative products, including those in the robust pipeline of PRINTed therapeutics, are positioned within specialized markets, ensuring value through targeted applications. Pricing structures are based on partnership scales and specific therapeutic use cases, benefiting both Addition and its clients through negotiated terms aligned with therapeutic outcomes achieved. In December 2025, Addition Therapeutics raised USD 100 mn in venture funding from new investors including SR One and Pivotal Life Sciences to further develop its non-viral gene therapy platform. The company plans to expand its product offerings and is targeting specific geographic regions for growth, particularly focusing on advancements in gene therapies to meet unmet medical needs.

The recent funding will support these initiatives, enhancing the company's capacity to deliver innovative solutions in genetic medicine.